Reason for request
Inclusion on the list of medicines reimbursed by National Health Insurance and approved for hospital use.
Clinical Benefit
| Substantial |
The actual benefit of OZURDEX 700 μg intravitreal implant in applicator is substantial. |
Clinical Added Value
| minor |
OZURDEX 700 μg intravitreal implant in applicator offers a minor improvement in actual benefit (IAB IV) in the management of the treatment of macular oedema and oedema following either branch retinal vein occlusion or central retinal vein occlusion. |
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
tyqmaHZ6q3PrZyUu
